

***Plasmodium falciparum*, Strain FCR-3/FMG (Gambia)**

Catalog No. MRA-736

Product Description: *Plasmodium falciparum* (*P. falciparum*), strain FCR-3/FMG (Gambia) was originally isolated in 1976 from the blood of a human patient collected in The Gambia, West Africa. MRA-736 was derived from ATCC® 30932™, which was deposited at ATCC® by W. Trager.

Lot¹: 70017000

Manufacturing Date: 20JUL2018

| TEST | SPECIFICATIONS | RESULTS |
|---|--|---|
| Identification by Giemsa Stain Microscopy^{2,3} | Blood-stage parasites present | Blood-stage parasites present |
| Antimalarial Susceptibility Profile (<i>in vitro</i>)² Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I® drug sensitivity assay ⁴ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine | Report results Report results Report results Report results Report results Report results | 55.3 ± 6.4 nM 7.6 ± 0.7 nM 131.9 ± 12.2 nM 588.1 ± 40.7 nM 141.7 ± 19.6 nM 276800 ± 38363 nM |
| Genotypic Analysis² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 480 base pairs) | Consistent with <i>P. falciparum</i> | Consistent with <i>P. falciparum</i> (Figure 1) |
| Functional Activity by PCR Amplification² MSP2 PCR amplicon analysis ⁵ | ~ 600 to 900 base pair amplicon | ~ 900 base pair amplicon |
| Level of Parasitemia Pre-freeze ^{6,7} Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8} Ring-stage parasitemia Total parasitemia | Report results ≥ 2% Report results ≥ 1% | 2.02% 3.56% 1.88% 3.75% |
| Viability^{2,9} | Growth in infected red blood cells | Growth in infected red blood cells |
| Sterility (21-day incubation)² Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic | No growth No growth No growth No growth No growth No growth No growth | No growth No growth No growth No growth No growth No growth No growth |
| Mycoplasma Contamination² DNA Detection by PCR | None detected | None detected |

¹MRA-736 was produced by cultivation of BEI Resources MR-MRA-736 lot 58319489 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 14 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

²Testing completed on vial post-freeze material.

³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].

⁵Primer sequences and conditions for PCR are available upon request.

⁶Testing completed on bulk material prior to vialing and freezing.

⁷Parasitemia was determined after 14 days post infection by microscopic counts of Giemsa-stained blood smears.

⁸Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.

⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 5 days post infection.

¹⁰Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-736 MSP2 Sequence

```
TTTTTGTTAC CTTTAATATT AAAAATGAAA GTAAATATAG CAACACATTC ATAAACAATG CTTATAATAT GAGTATAAGG
AGAAGTATGA CAGAAAAGTAA TCCTCCTACT GGTGCTAGTG GTAGTGCTGG TGGTAGTGCT GGTGGTAGTG CTGGTGGTAG
TGCTGGTGGT AGTGCTGGTG GKAGTGCTGG TGGTAGTGCT GGTGGTAGTG CTGGTGGTAG TGCTGGTGGW AGTGCTGGTG
GKAGTGCTGG KGGTAGTGCT GGTGGTAGTG CTGGTTCTGG TGATGGTAAT GGTGCTAATC CTGGTGCARA TGCTGAGAGA
AGTCCAAGTA CTCCCGCTAC TACCACAACCT ACCACAACCTA CTAATGATGC WKAAGCATCT ACCARTACCT CTTCAGAAAA
TCCAAATCAT AATAATGCCK AAACAAATCA AGCAAATAAA GAAACTCAA ATAACTCAA TGTTCAACAA GACTCTCAAA
C
```

/Heather Couch/

Heather Couch

23 SEP 2018

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

